Rethinking HEOR Market Access Integration: A Ca...

By João L. Carapinha

November 24, 2025

Early HEOR Market Access Integration In this brief interview on ISPOR, Indranil Bagchi asserts that HEOR market access integration must o...
Weight Loss: Advances in Hormone-Based Obesity Treatments
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurem...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit